U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPROMAZINE

SMILES

CN(C)CCCN1c2ccccc2Sc3ccc(cc31)Cl

InChI

InChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

Originator

Curator's Comment:: Chlorpromazine was synthesized in December 1951 in the laboratories of Rhône-Poiulenc, and became available on prescription in France in November 1952.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
37.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.31 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
135 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
247 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
81.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.1 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.05 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.48 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.52 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
CHLORPROMAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 75 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 52 years (range: 36.5-65.6 years)
Health Status: unhealthy
Condition: agitation
Age Group: 52 years (range: 36.5-65.6 years)
Sex: M+F
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Adverse event grade 5
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Drug-induced dystonia.
1975 May
Effects of chlorpromazine on bilirubin metabolism and biliary secretion in the rat.
1975 Oct
The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note.
1976 Nov
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
1992
Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens.
1992 Mar
Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRgamma1 isoform.
1999 Apr
[Intractable vomiting, convulsions and megaloblastic anemia: anamnesis, key to diagnosis].
1999 Jul 3
Tardive dystonia induced by risperidone.
1999 Jun
Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.
1999 Mar
Effect of some psychotropic drugs and a barbiturate on mycoplasmas.
2000 Apr
Synthesis and biological activity of N-acylphenothiazines.
2000 Apr
Double-blind crossover study of chlorpromazine and lorazepam in the treatment of behavioral problems during treatment of children with acute lymphoblastic leukaemia receiving glucocorticoids.
2000 Apr
Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds.
2000 Jul 28
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.
2000 Sep
Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice.
2001 Aug 1
Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts.
2001 Jul
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.
2001 Mar
Bipolar disorder after mefloquine treatment.
2001 May
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.
2001 May
Iatrogenic cardiopulmonary arrest during pediatric sedation with meperidine, promethazine, and chlorpromazine.
2001 Oct
[Models of drug treatment in the attention deficit disorder with hyperactivity].
2002 Feb
Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
2002 Nov-Dec
Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines.
2003 Jan
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
2003 Jun
Variant Creutzfeldt-Jakob disease.
2003 Mar
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.
2003 Mar
Sydenham's chorea may be a risk factor for drug induced parkinsonism.
2003 Sep
[Differences in prooxidant effect of neuroleptics haloperidol and aminazine].
2003 Sep-Oct
Two cases of deep vein thrombosis associated with antipsychotic drug use.
2004 Aug
Effects of lipopolysaccharide and chlorpromazine on glucocorticoid receptor-mediated gene transcription and immunoreactivity: a possible involvement of p38-MAP kinase.
2004 Dec
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?
2004 Mar
Drug-induced liver injury.
2004 Mar 1
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.
2004 May
Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland.
2005 Feb
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
2005 May
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.
2005 Nov
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.
2006 Apr 15
Frequency of high-risk use of QT-prolonging medications.
2006 Jun
Patents

Sample Use Guides

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day
Route of Administration: Other
In Vitro Use Guide
Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:05 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:05 UTC 2021
Record UNII
U42B7VYA4P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPROMAZINE
HSDB   INN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
CHLORPROMAZINUM
HPUS  
Common Name English
ESMIND
Common Name English
CHLORPROMAZINE [MART.]
Common Name English
2-CHLORO-10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE
Systematic Name English
CHLORPROMAZINUM [HPUS]
Common Name English
NSC-226514
Code English
SANOPRON
Common Name English
CHLORPROMAZINE [VANDF]
Common Name English
CHLORPROMAZINE [INN]
Common Name English
J2.794D
Code English
SKF-2601A
Code English
CHLORPROMAZINE [HSDB]
Common Name English
CHLORPROMAZINE [USP MONOGRAPH]
Common Name English
NSC-167745
Code English
PROPAPHENIN
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-
Systematic Name English
CPZ
Common Name English
3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYLPROPAN-1-AMINE
Systematic Name English
LARGACTILOTHIAZINE
Common Name English
WINTERMIN
Common Name English
FENACTIL
Common Name English
CHLORPROMAZINE [ORANGE BOOK]
Common Name English
THORAZINE
Brand Name English
NOVOMAZINA
Common Name English
CHLORPROMAZINE [MI]
Common Name English
AMINAZINE
Common Name English
CHLORPROMAZINE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AA01
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000175746
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
WHO-VATC QN05AA01
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.1
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NDF-RT N0000007544
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
NCI_THESAURUS C740
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
LIVERTOX 196
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL71
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
CAS
50-53-3
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
DRUG BANK
DB00477
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
IUPHAR
83
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
DRUG CENTRAL
621
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
HSDB
3033
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
NCI_THESAURUS
C367
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-045-8
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EVMPD
SUB06208MIG
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EPA CompTox
50-53-3
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
PUBCHEM
2726
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
INN
183
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
MERCK INDEX
M3461
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY Merck Index
LACTMED
Chlorpromazine
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
RXCUI
2403
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY RxNorm
FDA UNII
U42B7VYA4P
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
EVMPD
SUB01255MIG
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
MESH
D002746
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
WIKIPEDIA
CHLORPROMAZINE
Created by admin on Fri Jun 25 21:00:05 UTC 2021 , Edited by admin on Fri Jun 25 21:00:05 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDING PROTEIN->LIGAND
chlorpromazine displayed an approximately 1:1 [drug:AGP] binding stoichiometry; DETERMINED BY ITC
BINDING
Kd
METABOLIC ENZYME -> INHIBITOR
IC50
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: N-demethylation Pharmacological action: Phenothiazine antipsychotic
SUBSTRATE
Unidentified
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC